Premium Nahrungsergänzungsmittel | artgerecht

NAFLD Fibrosis Score: Calculation & Meaning

The NAFLD Fibrosis Score is a non-invasive tool used to estimate the degree of liver fibrosis in patients with non-alcoholic fatty liver disease, helping to avoid liver biopsy.

Regular tips about health Regular tips about health

Things worth knowing about "NAFLD Fibrosis Score"

The NAFLD Fibrosis Score is a non-invasive tool used to estimate the degree of liver fibrosis in patients with non-alcoholic fatty liver disease, helping to avoid liver biopsy.

What Is the NAFLD Fibrosis Score?

The NAFLD Fibrosis Score (NFS) is a non-invasive diagnostic tool used to estimate the severity of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). NAFLD refers to the accumulation of excess fat in the liver that is not caused by alcohol consumption. Over time, NAFLD can progress to fibrosis – the abnormal build-up of scar tissue in the liver – which impairs liver function and may lead to serious complications.

The NFS was developed to reduce the need for liver biopsy – an invasive tissue sampling procedure – by providing a reliable estimate of fibrosis stage using simple clinical and laboratory parameters.

How Is the NAFLD Fibrosis Score Calculated?

The NFS is calculated using six readily available clinical and laboratory variables:

Age (in years)
Body Mass Index (BMI) (kg/m²)
Presence of impaired fasting glucose or diabetes mellitus (yes/no)
AST/ALT ratio (ratio of liver enzymes aspartate aminotransferase to alanine aminotransferase)
Platelet count (x10&sup9;/L)
Serum albumin (g/dL)

The formula is:
NFS = –1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m²) + 1.13 × IFG/diabetes (yes=1, no=0) + 0.99 × AST/ALT ratio – 0.013 × platelets (x10&sup9;/L) – 0.66 × albumin (g/dL)

Interpretation of Results

The calculated score is interpreted using established cut-off values:

NFS < –1.455: Low probability of advanced fibrosis (F0–F2). Advanced fibrosis can be ruled out with high confidence.
NFS between –1.455 and 0.675: Indeterminate zone – further diagnostic evaluation is recommended.
NFS > 0.675: High probability of advanced fibrosis (F3–F4). Further workup or liver biopsy is indicated.

Clinical Relevance

The NAFLD Fibrosis Score is a valuable tool in hepatology and primary care settings. It allows clinicians to identify high-risk patients early and make informed decisions about the need for invasive procedures. Regular fibrosis assessment is particularly important in patients with known NAFLD, type 2 diabetes, metabolic syndrome, or obesity.

Advanced liver fibrosis increases the risk of:

Liver cirrhosis (extensive scarring of liver tissue)
Hepatocellular carcinoma (liver cancer)
Liver failure
Increased mortality from liver disease and cardiovascular events

Advantages and Limitations

Advantages

Non-invasive and easy to perform
Based on routinely available laboratory values
Well-validated across diverse patient populations
Helps avoid unnecessary liver biopsies
Cost-effective

Limitations

May be less accurate in certain groups (e.g., elderly patients or those with diabetes)
Does not provide a definitive answer in the indeterminate range
Does not replace histological diagnosis in ambiguous cases
Does not assess inflammatory activity (NASH activity)

NAFLD Fibrosis Score Compared to Other Scores

Several other non-invasive scoring systems exist for fibrosis assessment in NAFLD, including the FIB-4 index, the APRI score, and imaging-based methods such as liver elastography (FibroScan®). The NFS is considered one of the most thoroughly validated scores for NAFLD-specific fibrosis assessment and is recommended in international clinical guidelines.

References

Angulo P. et al. - The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007; 45(4): 846–854. (PubMed PMID: 17393509)
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) - EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 2016; 64(6): 1388–1402.
Chalasani N. et al. - The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67(1): 328–357.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.